Aripiprazole Tablet
Product Images NDC 16714-142

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 16714-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10mg3oscount (10mg3oscount)

This is a medication called Aripiprazole, in the form of tablets with 10 mg of the active ingredient. The usual dosage should be checked in the prescribing information provided. The medication guide should be dispensed separately for each patient. The medication should be stored in tightly closed containers at a temperature between 20°C to 25°C (68°F to 77°F). The manufacturer is Hetero Labs Limited, located in India. A batch code and a license number are provided for product tracking purposes.*

FDA Label Image

15mg3oscount (15mg3oscount)

This is a bottle of Aripiprazole tablets, USP with NDC number 16714-144-01 from NorthStar Healthcare Holdings. The bottle contains 30 tablets each with 15mg of Aripiprazole. This medication requires a prescription and patients should be given a medication guide which can be obtained from the website or by calling the supplier. The usual dosage and administration information can be found in the prescribing information. The medication should be stored in a tightly closed container at room temperature. The manufacturer of the tablets is Hetero Labs Limited based in India. The batch code is on the unvarnished area of the bottle.*

FDA Label Image

20mg3oscount (20mg3oscount)

This is a medication description for Aripiprazole Tablets USP, with each tablet containing 20 mg of Aripiprazole, used in accordance with the prescribing information for dosage and administration. It is recommended that the medication guide be dispensed to each patient, with the guide available on the manufacturer's website or by phone. The medication should be stored in tightly closed containers at controlled room temperature. The manufacturer is Northstar Healthcare Holdings with manufacturing done in India. Batch coding is present on the package for identification.*

FDA Label Image

2mg3oscount (2mg3oscount)

Aripiprazole Tablets USP 2mg, NDC 16714-141-01 is a medicine made by Northstar R LLC, manufactured by Hetero Labs Limited in India. The medication guide is provided separately for each thirty tablets, and information for dosage and administration can be found in the prescribing information. It is recommended to store the tablets in tightly closed containers at 20° to 25°C (68° to 77°F). The medication guide is available at the website www.northstarrxlic.com/products or by calling 1800-206-7821.*

FDA Label Image

30mg3oscount (30mg3oscount)

This is a medication called Aripiprazole manufactured by Hetero Labs Limited in India and distributed by Northstar Rx LLC in Memphis, TN. Each tablet contains 30mg of aripiprazole. It is advised to store it in a tightly closed container at room temperature. A medication guide is available at www.northstarrxlic.com/products or call 1800-206-7821. The usual dosage should be determined by a prescribing physician.*

FDA Label Image

5mg3oscount (5mg3oscount)

This is a medication information for Aripiprazole tablets with a strength of 5 mg, indicated for administration at a usual dosage. It also includes NDC and batch code information, manufacturers' details and storage recommendations. A separate medication guide is available for each patient. The text also suggests that the medication is made in India by Hetero Labs Limited for Northstar Rx LLC, and distributed in the United States.*

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

The given text provides information on the effect of other drugs on aripiprazole. It lists down specific drugs that can interact with CYP enzymes, such as ketoconazole and quinidine as inhibitors, and carbamazepine as an inducer. It also mentions some gastric acid blockers and other drugs like valproate, lithium, and lorazepam. The text further gives a graph showing the fold change and 90% CI of dehydro-aripiprazole with respect to reference without interacting drugs. Overall, the text aims to provide important information for healthcare professionals to consider while prescribing aripiprazole.*

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

The given text contains information on dosage adjustments and effects of Avripiprazole Fold Change in different population groups. It includes PK parameters such as AUCmax, CYP206 metabolism, and renal/hepatic impairment for individuals of different ages and genders. The text also provides a graph showing the percentage change in Avripiprazole Fold relative to the reference.*

FDA Label Image

Figure5 (Figure5)

This appears to be a tabular data that compares the effects of various factors on the metabolism and pharmacokinetics of a substance. The factors being compared include the level of metabolizer (poor vs. extensive), gender (female vs. male), age (16-64 vs. >65 years old), hepatic impairment (mild vs. moderate vs. severe vs. normal), and renal impairment (severe). The data shows the maximum effects on AUC and Cmax of the substance for each factor. Additionally, there is a table showing the fold change and confidence interval for Dehydro-Aripiprazole.*

FDA Label Image

Structure (Structure)

FDA Label Image

Figure 6 (Figure 6)

This appears to be a table and graph comparing the effectiveness of a drug called "Aripiprazole" versus a placebo in preventing relapse in a group of subjects over a period of time. The graph shows the proportion of subjects experiencing relapse over time, and the table shows the number of subjects at risk at various time points. No specific information about the study or its results is available beyond this.*

FDA Label Image

Figure 7 (Figure 7)

This appears to be a graph or chart displaying data related to a clinical trial for a drug called Ariplprazole and a placebo. The chart shows the proportion of subjects experiencing a relapse over time, with the number of subjects at risk decreasing over time. Unfortunately, without more context or information it is difficult to interpret the significance of these findings.*

FDA Label Image

Figure 8 (Figure 8)

This appears to be a chart or table related to a drug called Aripiprazole and its effectiveness in preventing relapse. The table shows the number of subjects at risk for relapse over time, with some receiving Aripiprazole and others receiving a placebo. The proportion of subjects with relapse is also included. However, without more context or additional information, it is unclear what type of study or condition the drug is used for.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.